|
Fusion Antibodies PLC on Wednesday said it has been picked for an antibody services project with a European-based global pharmaceutical company. The contract researcher providing therapeutic antibody discovery, design and optimisation services to the healthcare market said the deal is expected to be completed within the current financial year. It expects to generate revenue from the project of £175,000. The multi-target integrated therapeutic antibody services project is with the antibody centre of excellence ‘of a European-based global pharmaceutical company’. The pact includes humanisation and supply elements work. ‘Humanisation is the process required to make antibodies which were derived from non-human sequences, typically from mouse or rabbit antibodies, suitable for use as human therapeutics. Fusion will humanise a family of VHH antibody fragments for the client. The project also involves the expression, purification and supply of research materials,’ Fusion Antibodies said. ‘The selection of Fusion for this project again demonstrates the company’s ability to secure contracts with major pharmaceutical businesses. This is seen as a significant part of the company’s strategy of reducing dependence on more volatile smaller clients, but also in seeking to exploit the company’s novel technologies.’ Fusion shares were 0.4% lower at 15.19 pence each in London on Wednesday afternoon. Copyright 2025 Alliance News Ltd. All Rights Reserved.
|
